Literature DB >> 19858387

Changing the paradigm in conducting randomized clinical studies in advanced pancreatic cancer: an opportunity for better clinical development.

Josep Tabernero, Teresa Macarulla.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19858387     DOI： 10.1200/JCO.2009.23.3098

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  13 in total

1.  Chemotherapy: Gemcitabine remains the standard of care for pancreatic cancer.

Authors:  Jordan Berlin; Al B Benson
Journal:  Nat Rev Clin Oncol       Date:  2010-03       Impact factor: 66.675

2.  PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors.

Authors:  Funda Meric-Bernstam; Argun Akcakanat; Huiqin Chen; Kim-Anh Do; Takafumi Sangai; Farrell Adkins; Ana Maria Gonzalez-Angulo; Asif Rashid; Katherine Crosby; Mei Dong; Alexandria T Phan; Robert A Wolff; Sanjay Gupta; Gordon B Mills; James Yao
Journal:  Clin Cancer Res       Date:  2012-03-15       Impact factor: 12.531

3.  Triple approach strategy for patients with locally advanced pancreatic carcinoma.

Authors:  Alessandro Giardino; Roberto Girelli; Isabella Frigerio; Paolo Regi; Maurizio Cantore; Auriemma Alessandra; Annita Lusenti; Roberto Salvia; Claudio Bassi; Paolo Pederzoli
Journal:  HPB (Oxford)       Date:  2012-12-06       Impact factor: 3.647

Review 4.  Pancreatic biomarkers: could they be the answer?

Authors:  Angela Lamarca; Jaime Feliu
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

5.  A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.

Authors:  N V Rajeshkumar; Zeshaan A Rasheed; Elena García-García; Fernando López-Ríos; Kosaku Fujiwara; William H Matsui; Manuel Hidalgo
Journal:  Mol Cancer Ther       Date:  2010-07-26       Impact factor: 6.261

6.  A Multi-institutional Phase 2 Study of Imatinib Mesylate and Gemcitabine for First-Line Treatment of Advanced Pancreatic Cancer.

Authors:  Rebecca A Moss; Dirk Moore; Mary F Mulcahy; Kenneth Nahum; Biren Saraiya; Simantini Eddy; Martin Kleber; Elizabeth A Poplin
Journal:  Gastrointest Cancer Res       Date:  2012-05

7.  Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: a Sarah Cannon Research Institute phase II trial.

Authors:  Jeffrey R Infante; Hendrik-Tobias Arkenau; Johanna C Bendell; Mark S Rubin; David Waterhouse; George Tripp Jones; David R Spigel; Cassie M Lane; John D Hainsworth; Howard A Burris
Journal:  Cancer Biol Ther       Date:  2013-01-28       Impact factor: 4.742

Review 8.  TTD consensus document on the diagnosis and management of exocrine pancreatic cancer.

Authors:  M Benavides; A Abad; I Ales; A Carrato; E Díaz Rubio; J Gallego; J García-Foncillas; C Grávalos; B Laquente; C Pericay; F Rivera; J Tabernero; E Aranda
Journal:  Clin Transl Oncol       Date:  2014-04-12       Impact factor: 3.405

9.  Pancreatic cancer: why is it so hard to treat?

Authors:  Paul E Oberstein; Kenneth P Olive
Journal:  Therap Adv Gastroenterol       Date:  2013-07       Impact factor: 4.409

10.  Current and emerging therapies for the treatment of pancreatic cancer.

Authors:  Rebecca A Moss; Clifton Lee
Journal:  Onco Targets Ther       Date:  2010-09-07       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.